The emergence of SARS-CoV-2 antibody escape mutations highlights the urgent need for
broadly neutralizing therapeutics. We previously identified a human monoclonal antibody …

Abstract Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2
(SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results …

Several potent neutralizing antibodies against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) virus have been identified. However, antibody-dependent …

The replacement of the Omicron BA. 1 variant of SARS-CoV-2 by the BA. 2 and the rapid
growth of the BA. 5 sub lineage, which have both different sets of mutations in the spike …

Omicron variant strains encode large numbers of changes in the spike protein compared to
historical SARS-CoV-2 isolates. Although in vitro studies have suggested that several …

Improving clinical care for individuals infected with SARS-CoV-2 variants is a global health
priority. Small-molecule antivirals like remdesivir (RDV) and biologics such as human …

Neutralizing antibodies for the treatment of COVID-19 | Nature Biomedical Engineering Skip to
main content Thank you for visiting nature.com. You are using a browser version with limited …

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes
coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and …

To address the COVID-19 pandemic, there has been an unprecedented global effort to
advance potent neutralizing mAbs against SARS-CoV-2 as therapeutics. However, historical …

Summary SARS-CoV-2 neutralizing antibodies (NAbs) protect against COVID-19, making
them a focus of vaccine design. A safety concern regarding SARS-CoV-2 antibodies is …